journal
https://read.qxmd.com/read/36455192/financial-burden-in-blood-or-marrow-transplantation-survivors-during-the-covid-19-pandemic-a-bmtss-report
#1
JOURNAL ARTICLE
Smita Bhatia, Chen Dai, Lindsey Hageman, Jessica Wu, Elizabeth Schlichting, Arianna Siler, Erin Funk, Jessica Hicks, Shawn Lim, Nora Balas, Alysia Bosworth, Hok Sreng Te, Liton Francisco, Ravi Bhatia, Stephen J Forman, F Lennie Wong, Mukta Arora, Saro H Armenian, Daniel J Weisdorf, Wendy Landier
PURPOSE: The financial burden experienced by blood or marrow transplant (BMT) survivors during the COVID-19 pandemic remains unstudied. We evaluated the risk for high out-of-pocket medical costs and associated financial burden experienced by BMT survivors and a sibling comparison group during the COVID-19 pandemic. METHODS: This study included 2,370 BMT survivors and 750 siblings who completed the BMT Survivor Study survey during the pandemic. Participants reported employment status, out-of-pocket medical costs, and financial burden...
December 1, 2022: Journal of Clinical Oncology
https://read.qxmd.com/read/36455190/racial-and-ethnic-disparities-in-cervical-cancer-incidence-survival-and-mortality-by-histologic-subtype
#2
JOURNAL ARTICLE
Camryn M Cohen, Nicolas Wentzensen, Philip E Castle, Mark Schiffman, Rosemary Zuna, Rebecca C Arend, Megan A Clarke
PURPOSE: We conducted an integrated population-based analysis of histologic subtype-specific cervical cancer incidence, survival, and incidence-based mortality by race and ethnicity, with correction for hysterectomy prevalence. METHODS: Using the SEER 21 and 18 registries, we selected primary cases of malignant cervical cancer diagnosed among women ≥ 15 years. We evaluated age-adjusted incidence rates among cases diagnosed between 2000 and 2018 (SEER21) and incidence-based mortality rates among deaths from 2005 to 2018 (SEER18), per 100,000 person-years...
December 1, 2022: Journal of Clinical Oncology
https://read.qxmd.com/read/36455189/low-intensity-adjuvant-chemotherapy-for-breast-cancer-in-older-women-results-from-the-prospective-multicenter-hope-trial
#3
JOURNAL ARTICLE
Mina S Sedrak, Can-Lan Sun, Jingran Ji, Harvey J Cohen, Cary P Gross, William P Tew, Heidi D Klepin, Tanya M Wildes, Efrat Dotan, Rachel A Freedman, Tracey O'Connor, Selina Chow, Mary Ann Fenton, Beverly Moy, Andrew E Chapman, William Dale, Vani Katheria, Nicole M Kuderer, Gary H Lyman, Allison Magnuson, Hyman B Muss
PURPOSE: Older women with high-risk early breast cancer (EBC) benefit from adjuvant chemotherapy, but their treatment is frequently complicated by toxic side effects, resulting in dose reductions and delays. This makes it challenging for oncologists to maintain a relative dose intensity (RDI) ≥ 85%, as recommended for optimal curative-intent treatment. Understanding which women are at risk of receiving suboptimal RDI may inform treatment discussions and guide early, targeted supportive care or geriatric comanagement interventions...
December 1, 2022: Journal of Clinical Oncology
https://read.qxmd.com/read/36455187/decitabine-versus-hydroxyurea-for-advanced-proliferative-chronic-myelomonocytic-leukemia-results-of-a-randomized-phase-iii-trial-within-the-emsco-network
#4
JOURNAL ARTICLE
Raphael Itzykson, Valeria Santini, Sylvain Thepot, Lionel Ades, Cendrine Chaffaut, Aristoteles Giagounidis, Margot Morabito, Nathalie Droin, Michael Lübbert, Rosa Sapena, Stanislas Nimubona, Jean Goasguen, Eric Wattel, Gina Zini, Jose Miguel Torregrosa Diaz, Ulrich Germing, Anna Maria Pelizzari, Sophie Park, Nadja Jaekel, Georgia Metzgeroth, Francesco Onida, Robert Navarro, Andrea Patriarca, Aspasia Stamatoullas, Katharina Götze, Martin Puttrich, Sandra Mossuto, Eric Solary, Silke Gloaguen, Sylvie Chevret, Fatiha Chermat, Uwe Platzbecker, Pierre Fenaux
PURPOSE: Hydroxyurea (HY) is a reference treatment of advanced myeloproliferative neoplasms. We conducted a randomized phase III trial comparing decitabine (DAC) and HY in advanced myeloproliferative chronic myelomonocytic leukemias (CMML). PATIENTS AND METHODS: Newly diagnosed myeloproliferative CMML patients with advanced disease were randomly assigned 1:1 to intravenous DAC (20 mg/m2 /d days 1-5) or HY (1-4 g/d) in 28-day cycles. The primary end point was event-free survival (EFS), events being death and acute myelomonocytic leukemia (AML) transformation or progression...
December 1, 2022: Journal of Clinical Oncology
https://read.qxmd.com/read/36455171/reply-to-a-mangla-and-e-hindi%C3%A3
#5
JOURNAL ARTICLE
Marc D Moncrieff, Vernon K Sondak, John F Thompson, Jonathan S Zager
No abstract text is available yet for this article.
December 1, 2022: Journal of Clinical Oncology
https://read.qxmd.com/read/36455169/dissecting-the-need-for-adjuvant-therapy-in-patients-with-early-stage-melanoma-with-micrometastases
#6
LETTER
Ankit Mangla
No abstract text is available yet for this article.
December 1, 2022: Journal of Clinical Oncology
https://read.qxmd.com/read/36455168/pembrolizumab-versus-placebo-as-second-line-therapy-in-patients-from-asia-with-advanced-hepatocellular-carcinoma-a-randomized-double-blind-phase-iii-trial
#7
JOURNAL ARTICLE
Shukui Qin, Zhendong Chen, Weijia Fang, Zhenggang Ren, Ruocai Xu, Baek-Yeol Ryoo, Zhiqiang Meng, Yuxian Bai, Xiaoming Chen, Xiufeng Liu, Juxiang Xiao, Gwo Fuang Ho, Yimin Mao, Xin Wang, Jieer Ying, Jianfeng Li, Wenyan Zhong, Yu Zhou, Abby B Siegel, Chunyi Hao
PURPOSE: We evaluated the efficacy and safety of pembrolizumab in patients from Asia with previously treated advanced hepatocellular carcinoma (HCC). METHODS: In a double-blind, phase III trial, 453 patients with advanced HCC and progression during or after treatment with or intolerance to sorafenib or oxaliplatin-based chemotherapy were randomly assigned in a 2:1 ratio to receive pembrolizumab (200 mg) or placebo once every 3 weeks for ≤ 35 cycles plus best supportive care...
December 1, 2022: Journal of Clinical Oncology
https://read.qxmd.com/read/36455167/reassessing-the-benefits-and-harms-of-risk-reducing-medication-considering-the-persistent-risk-of-breast-cancer-mortality-in-estrogen-receptor-positive-breast-cancer
#8
JOURNAL ARTICLE
Jinani Jayasekera, Amy Zhao, Clyde Schechter, Kathryn Lowry, Jennifer M Yeh, Marc D Schwartz, Suzanne O'Neill, Karen J Wernli, Natasha Stout, Jeanne Mandelblatt, Allison W Kurian, Claudine Isaacs
PURPOSE: Recent studies, including a meta-analysis of 88 trials, have shown higher than expected rates of recurrence and death in hormone receptor-positive breast cancer. These new findings suggest a need to re-evaluate the use of risk-reducing medication to avoid invasive breast cancer and breast cancer death in high-risk women. METHODS: We adapted an established Cancer Intervention and Surveillance Modeling Network model to evaluate the lifetime benefits and harms of risk-reducing medication in women with a ≥ 3% 5-year risk of developing breast cancer according to the Breast Cancer Surveillance Consortium risk calculator...
December 1, 2022: Journal of Clinical Oncology
https://read.qxmd.com/read/36455165/risk-of-overusing-sentinel-node-biopsy-in-patients-with-thin-melanoma
#9
LETTER
Elif Hindié
No abstract text is available yet for this article.
December 1, 2022: Journal of Clinical Oncology
https://read.qxmd.com/read/36450104/how-we-manage-newly-diagnosed-multiple-myeloma-with-circulating-tumor-cells
#10
JOURNAL ARTICLE
Niels W C J van de Donk
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology , to patients seen in their own clinical practice...
November 30, 2022: Journal of Clinical Oncology
https://read.qxmd.com/read/36450101/risk-stratification-of-nonmuscle-invasive-bladder-cancer-and-innovative-approaches-to-management-of-ta-low-grade-tumors
#11
EDITORIAL
Sung Han Kim, Seth P Lerner
No abstract text is available yet for this article.
November 30, 2022: Journal of Clinical Oncology
https://read.qxmd.com/read/36446052/antibody-drug-conjugates-in-breast-cancer-searching-for-magic-bullets
#12
EDITORIAL
Cesar A Santa-Maria, Antonio C Wolff
No abstract text is available yet for this article.
November 29, 2022: Journal of Clinical Oncology
https://read.qxmd.com/read/36441987/state-variation-in-squamous-cell-carcinoma-of-the-anus-incidence-and-mortality-and-association-with-hiv-aids-and-smoking-in-the-united-states
#13
JOURNAL ARTICLE
Haluk Damgacioglu, Yueh-Yun Lin, Ana Patricia Ortiz, Chi-Fang Wu, Zahed Shahmoradi, Shiang Shiuan Shyu, Ruosha Li, Alan G Nyitray, Keith Sigel, Gary M Clifford, Naomi Jay, Vivian Colon Lopez, Gregory M Barnell, Elizabeth Y Chiao, Elizabeth A Stier, Karen J Ortiz-Ortiz, Jeslie M Ramos-Cartagena, Kalyani Sonawane, Ashish A Deshmukh
PURPOSE: Squamous cell carcinoma of the anus (SCCA) incidence and mortality rates are rising in the United States. Understanding state-level incidence and mortality patterns and associations with smoking and AIDS prevalence (key risk factors) could help unravel disparities and provide etiologic clues. METHODS: Using the US Cancer Statistics and the National Center for Health Statistics data sets, we estimated state-level SCCA incidence and mortality rates. Rate ratios (RRs) were calculated to compare incidence and mortality in 2014-2018 versus 2001-2005...
November 28, 2022: Journal of Clinical Oncology
https://read.qxmd.com/read/36417688/effect-of-the-covid-19-pandemic-on-place-of-death-among-medicaid-and-commercially-insured-patients-with-cancer-in-washington-state
#14
JOURNAL ARTICLE
Laura E Panattoni, Cara L McDermott, Li Li, Qin Sun, Catherine R Fedorenko, Hayley A Sanchez, Karma L Kreizenbeck, Veena Shankaran, Scott D Ramsey
PURPOSE: The COVID-19 pandemic-related disruptions in health care delivery might have affected end-of-life care in patients with cancer. We examined changes in place of death and hospice support for Medicaid and commercially insured patients during the pandemic. PATIENTS AND METHODS: We linked Washington State cancer registry records with claims from Medicaid and two commercial insurers for patients with solid tumor age 18-64 years. The study included 322 Medicaid and 162 commercial patients who died between March 2017 and June 2019 (pre-COVID-19), along with 90 Medicaid and 47 commercial patients who died between March and June 2020 (COVID-19)...
November 23, 2022: Journal of Clinical Oncology
https://read.qxmd.com/read/36413711/guilt-and-gratitude
#15
JOURNAL ARTICLE
Ilana Hellmann
No abstract text is available yet for this article.
November 22, 2022: Journal of Clinical Oncology
https://read.qxmd.com/read/36413710/overall-survival-with-daratumumab-bortezomib-and-dexamethasone-in-previously-treated-multiple-myeloma-castor-a-randomized-open-label-phase-iii-trial
#16
JOURNAL ARTICLE
Pieter Sonneveld, Asher Chanan-Khan, Katja Weisel, Ajay K Nooka, Tamas Masszi, Meral Beksac, Ivan Spicka, Vania Hungria, Markus Munder, Maria-Victoria Mateos, Tomer M Mark, Mark-David Levin, Tahamtan Ahmadi, Xiang Qin, Wendy Garvin Mayo, Xue Gai, Jodi Carey, Robin Carson, Andrew Spencer
PURPOSE: At the primary analysis of CASTOR (median follow-up, 7.4 months), daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged progression-free survival versus bortezomib and dexamethasone (Vd) alone in relapsed or refractory multiple myeloma (RRMM). We report updated efficacy and safety results at the final analysis for overall survival (OS). METHODS: CASTOR was a multicenter, randomized, open-label, phase III study during which eligible patients with ≥ 1 line of prior therapy were randomly assigned to Vd (up to eight cycles) with or without daratumumab (until disease progression)...
November 22, 2022: Journal of Clinical Oncology
https://read.qxmd.com/read/36409969/phase-iib-randomized-placebo-controlled-dose-escalating-double-blind-study-of-cannabidiol-oil-for-the-relief-of-symptoms-in-advanced-cancer-medcan1-cbd
#17
JOURNAL ARTICLE
Janet Hardy, Ristan Greer, Georgie Huggett, Alison Kearney, Taylan Gurgenci, Phillip Good
PURPOSE: To determine whether cannabidiol (CBD) oil can improve symptom distress in patients with advanced cancer receiving palliative care. METHODS: Participants were adults with advanced cancer and symptom distress (Edmonton Symptom Assessment Scale [ESAS] total score of ≥ 10/90) who received titrated CBD oil 100 mg/mL, 0.5 mL once daily to 2 mL three times a day, or matched placebo for 28 days. The primary outcome was ESAS total symptom distress score (TSDS) at day 14...
November 21, 2022: Journal of Clinical Oncology
https://read.qxmd.com/read/36399695/three-year-update-of-tisagenlecleucel-in-pediatric-and-young-adult-patients-with-relapsed-refractory-acute-lymphoblastic-leukemia-in-the-eliana-trial
#18
JOURNAL ARTICLE
Theodore W Laetsch, Shannon L Maude, Susana Rives, Hidefumi Hiramatsu, Henrique Bittencourt, Peter Bader, André Baruchel, Michael Boyer, Barbara De Moerloose, Muna Qayed, Jochen Buechner, Michael A Pulsipher, Gary Douglas Myers, Heather E Stefanski, Paul L Martin, Eneida Nemecek, Christina Peters, Gregory Yanik, Seong Lin Khaw, Kara L Davis, Joerg Krueger, Adriana Balduzzi, Nicolas Boissel, Ranjan Tiwari, Darragh O'Donovan, Stephan A Grupp
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. In the primary analysis of the global phase II ELIANA trial (ClinicalTrials.gov identifier: NCT02435849), tisagenlecleucel provided an overall remission rate of 81% in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), with 59% of responders remaining relapse-free at 12 months...
November 18, 2022: Journal of Clinical Oncology
https://read.qxmd.com/read/36399693/-jco-turns-40
#19
EDITORIAL
Kathy D Miller, Jonathan W Friedberg
No abstract text is available yet for this article.
November 18, 2022: Journal of Clinical Oncology
https://read.qxmd.com/read/36395435/zanubrutinib-versus-ibrutinib-in-relapsed-refractory-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma-interim-analysis-of-a-randomized-phase-iii-trial
#20
JOURNAL ARTICLE
Peter Hillmen, Barbara Eichhorst, Jennifer R Brown, Nicole Lamanna, Susan M O'Brien, Constantine S Tam, Lugui Qiu, Maciej Kazmierczak, Keshu Zhou, Martin Šimkovič, Jiří Mayer, Amanda Gillespie-Twardy, Mazyar Shadman, Alessandra Ferrajoli, Peter S Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Österborg, Habte A Yimer, Tommi Salmi, Meng Ji, Jessica Yecies, Adam Idoine, Kenneth Wu, Jane Huang, Wojciech Jurczak
PURPOSE: Zanubrutinib is a potent, irreversible next-generation Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and minimize off-target kinase inhibition. We hypothesized that complete/sustained BTK occupancy may improve efficacy outcomes and increased BTK specificity may minimize off-target inhibition-related toxicities. PATIENTS AND METHODS: ALPINE (ClinicalTrials.gov identifier: NCT03734016) is a global, randomized, open-label phase III study of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia...
November 17, 2022: Journal of Clinical Oncology
journal
journal
20146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.